Prevalence of Enteric Infections in Patients on Immune Checkpoint Inhibitors and Impact on Management and Outcomes
The Oncologist · 2024
DOI: 10.1093/oncolo/oyad226 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2024. Verfasst von Patrick T Magahis und 6 weiteren Autor:innen. Beteiligte Einrichtung: M.D. Program, Weill Cornell Medical College of Cornell University, New York, NY, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Colitis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIH, NCI.
Abstract (Originalsprache)
Background
Stool pathogen testing is recommended as part of the initial evaluation for patients with new-onset diarrhea on immune checkpoint inhibitors (ICIs), yet its significance has not been well-studied. We aimed to determine the impact of multiplex gastrointestinal (GI) pathogen PCR testing on the clinical course and use of immunosuppressive therapy in patients who develop diarrhea on ICIs.
Methods
This retrospective cohort included individuals who underwent GI pathogen panel PCR for diarrhea on ICIs at Memorial Sloan Kettering between 7/2015 and 7/2021. The primary outcome was use of immunosuppressive therapy for suspected immunotherapy-related enterocolitis (irEC). Secondary outcomes included diarrhea severity and endoscopic and histologic disease patterns.
Results
Among 521 ICI-treated patients tested for GI pathogens, 61 (11.7%) had a positive PCR. Compared to patients without detectable infections, patients with infections had more frequent grades 3-4 diarrhea (37.7% vs. 19.6%, P < .01) and colitis (39.3% vs. 14.7%, P < .01). However, patients with infections did not have higher rates of persistent or recurrent diarrhea and were less likely to receive steroids (P < .01) and second-line immunosuppressive agents (P = .03). In 105 patients with lower endoscopy, similar trends were observed and no differences in endoscopic severity or histologic patterns were noted between groups.
Conclusions
GI infections in ICI-treated patients presenting with diarrhea are linked to more severe but self-limited clinical presentations and may be optimally treated with observation and supportive care alone. Routine and timely stool pathogen testing may help avert unnecessary empiric immunosuppression for suspected irEC, which has been linked to blunted antitumor responses and numerous adverse effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- M.D. Program, Weill Cornell Medical College of Cornell University, New York, NY, USA.
- Gastroenterology, Hepatology, and Nutrition Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Infectious Diseases, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Clinical Microbiology Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Melanoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
ORCID-Profile: Patrick T Magahis, Deepika Satish, Monika Laszkowska, David M Faleck
Förderung
- NCI NIH HHS
- NIH
- NCI
- Cancer Center Support
Zitieren
APA
Magahis, P. T., Satish, D., Esther Babady, N., Kamboj, M., Postow, M. A., Laszkowska, M., & Faleck, D. M. (2024). Prevalence of Enteric Infections in Patients on Immune Checkpoint Inhibitors and Impact on Management and Outcomes. The Oncologist. https://doi.org/10.1093/oncolo/oyad226
Vancouver
Magahis PT, Satish D, Esther Babady N, Kamboj M, Postow MA, Laszkowska M, et al. Prevalence of Enteric Infections in Patients on Immune Checkpoint Inhibitors and Impact on Management and Outcomes. The Oncologist. 2024. doi:10.1093/oncolo/oyad226
BibTeX
@article{Magahis2024,
author = {Magahis, Patrick T and Satish, Deepika and Esther Babady, Ngolela and Kamboj, Mini and Postow, Michael A and Laszkowska, Monika and Faleck, David M},
title = {Prevalence of Enteric Infections in Patients on Immune Checkpoint Inhibitors and Impact on Management and Outcomes},
journal = {The Oncologist},
year = {2024},
doi = {10.1093/oncolo/oyad226}
}
EUVIMED